. The burden of healthcare-associated Clostridium difficile infection in a non-metropolitan setting. Journal of Hospital Infection, 95 (4), 387-393.
Introduction
Clostridium difficile infection (CDI) is a major cause of healthcare associated diarrhoea in industrialised countries and is associated with considerable morbidity and mortality. 1 In Australia, the annual incidence of hospital-identified CDI was 4.03 cases/10,000 patient days in 2012. 2 Risk is increased by antimicrobial use and/or immunosuppression. 3 Other putative risk factors include gastrointestinal surgery, gastric acid-suppressive therapy and prolonged hospital stay. 3 Healthcare associated Clostridium difficile infection (HCA-CDI) has been associated with increased length of stay (LOS), additional costs from hospitalisation 4 and antimicrobial treatment, 3 and indirect costs such as productivity losses. 5 Most antimicrobials have been related to CDI, with lincosamides (e.g. clindamycin), third generation cephalosporins (e.g. ceftriaxone), and broad-spectrum penicillins (e.g. amoxicillin/clavulanic acid) showing strong associations. 6 Fluoroquinolones have been particularly associated with the hypervirulent NAP1/027 strain. 7 There is probable association between proton pump inhibitor (PPI) use and CDI, with the combination of PPIs and antimicrobials carrying a greater risk than either alone. 8 Antimicrobial stewardship programs (ASPs) should be employed to reduce the incidence of HCA-CDI.
increasing community acquisition of CDI may cloud interpretation of HCA-CDI rates. 2 Antimicrobial stewardship (AMS) interventions targeting HCA-CDI have predominantly been conducted in metropolitan teaching hospitals, at single sites or within a defined clinical area. [9] [10] [11] [12] [13] Very limited data exist on the burden of HCA-CDI in Australia, particularly in regional and rural settings. 14 To our knowledge this is the first study to examine a multisite ASP in relation to HCA-CDI rates in the nonmetropolitan setting.
The aims of our study were: to describe HCA-CDI rates before and after an ASP; to measure LOS and hospital costs in HCA-CDI patients across multiple hospital sites;
to compare prior antimicrobial and PPI use in HCA-CDI patients with the background use; and to assess appropriateness of HCA-CDI antimicrobial treatment according to guidelines.
Methods

Setting
From December 2010 to April 2016, a comparative before-and-after intervention study on the burden of HCA-CDI was performed across the nine public hospitals (1000 total beds) of Illawarra Shoalhaven Local Health District (ISLHD) in south eastern New South Wales (NSW), Australia. The district services 390,000 residents across a catchment that begins one hour south of Sydney, and extends 250km along a coastal strip. The three largest hospitals comprise one principal referral hospital (550 beds), a large acute hospital (150 beds) and a medium acute hospital (100 beds). The remaining six hospitals are either small acute or mixed sub-and non-acute. 15 This study employed Plan, Do, Study, Act (PDSA) quality improvement methodology.
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Antimicrobial Stewardship
In May and June 2012, an ASP supported by a computerised clinical decision support system (CDSS; GuidanceMS ®17 ) was uniformly implemented across the district's nine hospitals. In addition to the CDSS, the ASP involved a restriction policy, whereby broad spectrum antimicrobials were only stocked in pharmacy (with supply contingent on CDSS approval) or specialist areas (i.e. intensive care unit [ICU], emergency department, haematology/oncology ward). An education campaign involved regular departmental presentations, and an intranet webpage was established to improve access to guidelines. Regular AMS rounds occurred at the three largest hospitals, and an antimicrobial advice telephone hotline was established across the district to support the smaller hospitals without onsite AMS clinicians. See Figure 1 for the study flowchart. There were no major changes to infection control policies related to either Clostridium difficile or hand hygiene during the study period. 3 was assessed during AMS rounds or retrospectively from medical notes.
Results were presented to the AMS, drug and therapeutics, and infection control committees.
Clostridium difficile laboratory testing
From December 2010, our laboratory protocol subjected all diarrhoeal stools to which could also detect the NAP1/027 strain.
Effect of HCA-CDI on LOS and hospital costs
LOS and hospital cost analysis was performed only for the three acute hospitals due to a shortage of matched controls and other confounders for LOS at smaller hospitals (e.g. nursing home availability, social factors). Definitions for HCA-CDI were: HCAhealthcare facility onset, diarrhoea onset >48 hours after admission; HCA-community onset, diarrhoea onset in the community or <48 hours after admission, but within four weeks of last discharge. 18 Demographic data for HCA-CDI cases did not differ significantly between hospitals, or between the two types of HCA-CDI (data not shown).
A post hoc analysis of LOS and hospital costs was conducted for those HCA-CDI 
Statistical analyses
Interrupted time series analysis 20 was used to assess HCA-CDI rates at the three large hospitals (due to comparability of acute OBD data). Data were included from In non-severe HCA-CDI treated at the acute hospitals (N=95), oral metronidazole was initiated in 78 (82%) cases. Oral vancomycin plus oral metronidazole was used in eight (8%) cases, where metronidazole alone would have sufficed. 3 No therapy was given in nine non-severe cases, due to cessation of diarrhoea with or without identification of an alternative correctable cause. In the severe HCA-CDI group (N=8), oral metronidazole was initiated in 4 (50%) cases, where oral vancomycin, intravenous metronidazole or a combination was indicated. In those cases a relevant AMS intervention was made.
Discussion
Our study describes the relationship between HCA-CDI rates and a multisite ASP supported by a CDSS, education and antimicrobial restriction combined with targeted audit and feedback. Implementation of an ASP was temporally associated with stable HCA-CDI rates. Targeted interventions may help to combat the waning of the initial impact of a program over time. We found that in an Australian non-metropolitan setting, LOS and hospital costs were significantly increased in HCA-CDI patients when compared with matched controls. Increased antimicrobial and PPI use in patients with HCA-CDI were consistent with previous reports. 6, 8 Although the initial treatment of non-severe HCA-CDI cases predominantly matched guidelines, there was concerning use of oral metronidazole in half of the severe cases (albeit with small numbers). This was similar to previous findings elsewhere, 21 likely resulting from under-recognition of severity criteria. 3, 22 HCA-CDI has been associated with increased LOS and hospital costs. 4 Most studies evaluating these effects were either epidemiological studies 23, 24 or performed in the metropolitan setting. 10 To our knowledge this is the first study to combine evaluation of the burden of HCA-CDI with multisite ASP implementation in a regional and rural setting. Comparison with matched controls 11, 25 allowed for a pragmatic approach to identifying additional LOS and hospital costs associated with HCA-CDI. For those patients with LOS ≥ 8 days, there was a 42% increase in hospital costs in HCA-CDI patients compared with controls, despite similar LOS in those groups. This highlighted the increased cost of caring for HCA-CDI patients additional to greater LOS, and alleviated the potential for time-dependent biases.
There were several limitations to this study. We included all positive Clostridium difficile tests during the targeted intervention phase, as the frequency of daily diarrhoeal episodes was unreliably documented. Alternative causes of diarrhoea may have been present in some patients carrying Clostridium difficile. We could not attribute the increase in LOS and hospital costs to HCA-CDI alone. Alternative statistical methods such as multi-state modelling 26 to account for time-dependent biases, and propensity matching 4 to accurately estimate the impacts of CDI have been proposed. To account for those limitations, we applied the case-control methodology in two additional subsets: the "long-stay" patients (≥8 days, the median time-to-onset of HCA-CDI) and only those treated for HCA-CDI. Those results were in line with our primary evaluation, emphasising the high LOS and cost burden of HCA-CDI. As expected, gastrointestinal DRGs were overrepresented. In some cases the primary DRG may have been allocated to gastrointestinal due to CDI severity or duration.
Community cases could not be accurately assessed with the current study resources.
Of 120 HCA-CDI cases, only 91 were eventually analysed for LOS and cost. Our study demonstrates the high burden of HCA-CDI in a non-metropolitan setting.
While it confirms the association between high-risk antimicrobial use and HCA-CDI, it also identifies the possibility of under-recognition of CDI severity criteria during treatment initiation. Targeted audit and feedback interventions may be a useful way of consolidating the effects of a multisite ASP, contributing to sustainability, which remains one of the major challenges of contemporary antimicrobial stewardship. Your patient X (MRN: 111111) was diagnosed with C. diff diarrhoea on dd/mm/yyyy.
Figure legends
Potential risk factors for your patient included:
(As appropriate)
• Proton pump inhibitor use -
• Anti-peristaltic use -
• Prior GI surgery - Clostridium difficile infection, data included for the three large acute hospitals of the health district; OBDs, occupied bed days; LCI, lower 95% confidence interval; UCI, upper 95% confidence interval; a adjusted for first order autocorrelation;
